Plasma Derived Therapy Market

Report Overview

The global plasma derived therapy market was pegged at US$ 25.4 billion in 2021 and is expected to witness a CAGR of 6.2% during the forecast period. 

Market Fundamentals 

Plasma is the clear, straw-colored liquid portion of blood that persists after red blood cells (RBCs), white blood cells (WBCs), platelets, and other cellular components are removed. It is the major component of blood and accounts for about 55% of blood content. Plasma contains water, salts, enzymes, antibodies, and other proteins. Plasma is separated from the blood by a process known as plasmapheresis. Further, proteins such as immunoglobulin, clotting factors, and albumin are derived from plasma. This therapy replaces missing or deficient proteins that allow individuals to lead healthy and more productive lives. It is used in the treatment of rare, life-threatening, chronic, and genetic diseases, such as immune deficiencies, pulmonary disorders, neurological disorders, shock & trauma, liver cirrhosis, and infectious diseases (tetanus, hepatitis, COVID-19 [still under clinical trials] and rabies).The use of Protein-rich plasma (PRP) in orthobiologic has recently won popularity as it plays a significant role in the bone & tissue repair process.

[230230]

Market Dynamics

The global plasma derived therapy market is mainly driven by the growing use of immunoglobulins in various therapeutic areas and the rising prevalence of life-threatening diseases such as immunodeficiency diseases and hemophilia. Awareness of blood & plasma donation and increasing research & development activities are also playing a pivotal role in contributing to market growth globally. Moreover, the growing adoption of PRP treatments in cosmetics, dermatology, dental and oral surgeries are also expected to offer significant growth in the market. However, the excessive cost of therapy and lack of reimbursement policies is likely to restrain market growth to a certain extent.

Market Ecosystem

The global plasma derived therapy market has been analyzed from four perspectives: Protein Derived, Application, End User, and Region. 

Plasma Derived Therapy Market by Protein Derived

Based on protein derived, the market has been segmented into immunoglobulin, clotting factors, albumin, and others. The immunoglobulin segment is estimated to hold the highest share during the forecast period owing to its benefits when used for the treatment of various diseases. Immunoglobulin (also known as an antibody) is used by the immune system of the body to neutralize pathogens such as pathogenic bacteria and viruses. Therefore, immunoglobulins are derived from the plasma of a recovered patient and are used to immunize patients of various autoimmune, infectious, and idiopathic diseases. The clinical use of immunoglobulins is increasing owing to its application in several conditions such as autoimmune disorders, acute inflammatory conditions, etc.

Plasma Derived Therapy Market by Application

[634232]

Based on application, the market has been segmented into infectious diseases, hereditary diseases, and others. The hereditary diseases segment is expected to hold the highest share during the forecast period. Hereditary diseases treated by plasma derived therapy include hemophilia, primary immunodeficiency disorder (PID), hereditary angioedema, and von Willebrand disease, among others. Plasma derived therapy is key for patients suffering from rare diseases like hemophilia and inhibitor deficiency, etc. According to the European Copenhagen economics, it was estimated that more than one million Europeans get affected by one of the twelve most common rare diseases that can be treated with plasma-derived therapies. Some of these diseases, such as primary immunodeficiency disease (PID), have no other treatments besides plasma-derived therapies.

Infectious diseases treated by plasma derived therapy include H1N1, COVID-19 (still under clinical trials), and hepatitis, among others. The growth of the hereditary diseases segment can largely be attributed to its high prevalence and growing awareness about its treatment by plasma derived therapy. Plasma therapy also has significant use in dermatology as it removes wrinkles and fine lines and improves skin tone & texture.

Plasma Derived Therapy Market by End User

Based on end user, the market has been segmented into hospitals, clinics, and research institutes. The hospitals & clinics segment is expected to dominate the plasma derived therapy market with the highest share during the forecast period. The growth of the segment can be attributed to the frequent visits of patients to hospitals for diagnosis and treatment of various hematological and immunological disorders.

Plasma Derived Therapy Market by Region

Based on region, the global plasma derived therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America dominated the plasma derived therapy market, followed by the Asia Pacific. The large share of North America in the global market can be attributed to the early approval of plasma derived products and the growing use of immunoglobulin in various therapeutic areas. For instance, since the detection of the first case of COVID-19 in the U.S. on January 19, 2020, the U.S. FDA has ramped up medical countermeasures to treat and prevent COVID-19. U.S. government has collaborated with multiple non-government organizations and biotech companies to develop “hyperimmune” treatment products from convalescent plasma to boost the immune response of infected patients. Furthermore, advanced healthcare infrastructure for storing and maintaining high-quality source plasma has played a crucial role in the growth of this region in the global plasma derived therapy market.

Competitive Landscape

Some of the prominent players operating in the plasma derived therapy market are 

• Takeda Pharmaceutical Company Limited
• Biotest AG
• CSL Limited
• Grifols, S.A.
• Kedrion S.p.A
• LFB
• Bio Products Laboratory U.S.A., Inc., 
• China Biologic Products Holdings, Inc.
• Octapharma AG
• Emergent BioSolutions Inc., among others

Strategic Developments

• In May 2021, Liminal BioSciences entered into an agreement with Kedrion to divest its plasma collection and plasma-derived therapeutics business
• In Oct 2020, the Takeda group began manufacturing COVID-19 plasma treatment ahead of approval
• In June 2020, Bio Products Laboratory USA Launched Plasma Therapies, Entered COVID-19 Fray

Frequently Asked Questions About This Report